NRIX

Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX

Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% Upside

Mizuho raises Nurix stock price target to $34 on Roche deal

Baird reiterates Nurix stock Outperform rating at $33 target

Truist raises Nurix stock price target to $34 on Roche deal

Nurix stock price target raised to $33 by RBC on partnership outlook

Nurix stock price target raised to $34 by H.C. Wainwright

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Enterprise value to EBIT forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX

Nurix Therapeutics 3Q 2026: Revenue $9.04M, EPS $(0.81) — 10-Q Summary

Nurix reports Q2 2026: $9.0M revenue, $89.5M net loss, $443.5M cash; Roche collaboration announced

Nurix Therapeutics stock hits 52-week high at $24.93

Enterprise value to revenue forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX

Price to sales forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX

Oppenheimer reiterates Nurix stock rating on BTK degrader potential